Tomoki Nakamura1, Katsuyuki Kusuzaki2, Takao Matsubara3, Hiroaki Murata4, Tomohito Hagi5, Kunihiro Asanuma5, Akihiro Sudo5. 1. Department of Orthopaedic Surgery, Mie University Postgraduate School of Medicine, Edobashi 2-174, Tsu-city, 514-8507, Japan. Electronic address: tomoki66@clin.medic.mie-u.ac.jp. 2. Department of Musculoskeletal Oncology, Takai Hospital, Kuranosho 470-8, Tenri, 632-0006, Japan. 3. Matsubara Orthopaedic Clinic. Shiroyama 3-4-25, Tsu-city, 514-0818, Japan. 4. Department of Orthopaedic Surgery, Matsushita Memorial Hospital, Moriguchi-City, 570-8540, Japan. 5. Department of Orthopaedic Surgery, Mie University Postgraduate School of Medicine, Edobashi 2-174, Tsu-city, 514-8507, Japan.
Abstract
BACKGROUND: We investigated the long-term clinical efficacy of acridine orange (AO) therapy on the inhibition of local recurrence after marginal or intra-lesional tumor resection in high-grade soft tissue sarcomas (STSs). METHODS: Our study consisted of 48 patients with STSs who received AO therapy after marginal or intra-lesional resection. The median and mean follow-up durations were 76 and 78 months, respectively. Our AO therapy procedure was combined with photodynamic surgery, photodynamic therapy, and radiodynamic therapy. RESULTS: There were 25 men and 23 women, with a mean age of 46 years. The average tumor size at surgery was 8.5 cm. At the last follow-up, 11 patients developed local recurrence. The 5- and 10-year local recurrence-free rates were 78.9% and 73.3%, respectively. In multivariate analysis, tumor size remained significant for local control. None of the patients developed systemic or local complications. All patients recovered activities of daily life before AO therapy. CONCLUSION: AO therapy can be performed in safety and may be a useful therapy for acquiring long-term local control in patients with high-grade STSs. Tumor size is an important factor for the indication of AO therapy.
BACKGROUND: We investigated the long-term clinical efficacy of acridine orange (AO) therapy on the inhibition of local recurrence after marginal or intra-lesional tumor resection in high-grade soft tissue sarcomas (STSs). METHODS: Our study consisted of 48 patients with STSs who received AO therapy after marginal or intra-lesional resection. The median and mean follow-up durations were 76 and 78 months, respectively. Our AO therapy procedure was combined with photodynamic surgery, photodynamic therapy, and radiodynamic therapy. RESULTS: There were 25 men and 23 women, with a mean age of 46 years. The average tumor size at surgery was 8.5 cm. At the last follow-up, 11 patients developed local recurrence. The 5- and 10-year local recurrence-free rates were 78.9% and 73.3%, respectively. In multivariate analysis, tumor size remained significant for local control. None of the patients developed systemic or local complications. All patients recovered activities of daily life before AO therapy. CONCLUSION:AO therapy can be performed in safety and may be a useful therapy for acquiring long-term local control in patients with high-grade STSs. Tumor size is an important factor for the indication of AO therapy.
Authors: Stefania Lenna; Chiara Bellotti; Serena Duchi; Elisa Martella; Marta Columbaro; Barbara Dozza; Marco Ballestri; Andrea Guerrini; Giovanna Sotgiu; Tommaso Frisoni; Luca Cevolani; Greta Varchi; Mauro Ferrari; Davide Maria Donati; Enrico Lucarelli Journal: J Exp Clin Cancer Res Date: 2020-02-22